Profil
Ira Wallis has been Vice President of Regulatory Affairs for Tercica, Inc. since March 2003.
He was Senior Director and Head of Regulatory Affairs for Dynavax Technologies Corporation from May 2001 to January 2003 and a Director and Head of Regulatory Affairs for Cerus Corporation from July 1996 to April 2001.
Dr. Wallis was an Associate Director and Manager of Regulatory Affairs for Genentech, Inc. from 1990 to 1996 and Manager of Regulatory Affairs for Sandoz Pharmaceutical Corporation from 1987 to 1989.
He received a BA degree in Zoology from American International College and a PhD in Neurophysiology from the State University of New York.
Anciens postes connus de Ira Wallis
| Sociétés | Poste | Fin |
|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Conseiller Juridique Général | 03/02/2014 |
| DYNAVAX TECHNOLOGIES CORPORATION | Conseiller Juridique Général | 01/01/2003 |
| CERUS CORPORATION | Directeur/Membre du Conseil | 01/04/2001 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Conseiller Juridique Général | 01/01/1996 |
| Sandoz Pharmaceuticals Corp. | Conseiller Juridique Général | 01/01/1989 |
Formation de Ira Wallis
| American International College | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| CERUS CORPORATION | Health Technology |
| Entreprise privées | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Sandoz Pharmaceuticals Corp. |
